SG10201701331SA - Methods for treating or preventing asthma by administering an il-4r antagonist - Google Patents

Methods for treating or preventing asthma by administering an il-4r antagonist

Info

Publication number
SG10201701331SA
SG10201701331SA SG10201701331SA SG10201701331SA SG10201701331SA SG 10201701331S A SG10201701331S A SG 10201701331SA SG 10201701331S A SG10201701331S A SG 10201701331SA SG 10201701331S A SG10201701331S A SG 10201701331SA SG 10201701331S A SG10201701331S A SG 10201701331SA
Authority
SG
Singapore
Prior art keywords
antagonist
administering
treating
methods
preventing asthma
Prior art date
Application number
SG10201701331SA
Inventor
Marius Ardeleanu
Namita Gandhi
Neil Graham
Stephane C Kirkesseli
Sudeep Kundu
Allen Radin
Ross E Rocklin
Steven Weinstein
Hamilton Jennifer Davidson
Jeffrey Ming
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50148186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201701331S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of SG10201701331SA publication Critical patent/SG10201701331SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Otolaryngology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
SG10201701331SA 2012-08-21 2013-08-20 Methods for treating or preventing asthma by administering an il-4r antagonist SG10201701331SA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261691625P 2012-08-21 2012-08-21
US201361758097P 2013-01-29 2013-01-29
US201361761279P 2013-02-06 2013-02-06
US201361783796P 2013-03-14 2013-03-14
US201361805797P 2013-03-27 2013-03-27
FR1356994 2013-07-16

Publications (1)

Publication Number Publication Date
SG10201701331SA true SG10201701331SA (en) 2017-04-27

Family

ID=50148186

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201500889TA SG11201500889TA (en) 2012-08-21 2013-08-20 Methods for treating or preventing asthma by administering an il-4r antagonist
SG10201701331SA SG10201701331SA (en) 2012-08-21 2013-08-20 Methods for treating or preventing asthma by administering an il-4r antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201500889TA SG11201500889TA (en) 2012-08-21 2013-08-20 Methods for treating or preventing asthma by administering an il-4r antagonist

Country Status (28)

Country Link
US (4) US9574004B2 (en)
EP (4) EP3470432B1 (en)
JP (4) JP6306588B2 (en)
KR (6) KR102386304B1 (en)
CN (2) CN104755495A (en)
AR (1) AR092177A1 (en)
AU (4) AU2013305945B2 (en)
BR (1) BR112015003590A8 (en)
CA (2) CA2882416A1 (en)
DK (1) DK2888281T3 (en)
ES (3) ES2971088T3 (en)
HR (1) HRP20181963T1 (en)
HU (1) HUE064945T2 (en)
IL (3) IL293398B2 (en)
IN (1) IN2015KN00414A (en)
LT (1) LT2888281T (en)
MX (1) MX371344B (en)
NZ (3) NZ744109A (en)
PL (3) PL3470432T3 (en)
PT (2) PT3470432T (en)
PY (1) PY1337526A (en)
RS (1) RS58091B1 (en)
RU (1) RU2690675C2 (en)
SG (2) SG11201500889TA (en)
SI (1) SI2888281T1 (en)
TW (1) TWI656880B (en)
UY (1) UY34984A (en)
WO (1) WO2014031610A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
BR112013008366B1 (en) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc STABLE LIQUID PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-HUMAN INTERLEUKIN-4 ALPHA RECEPTOR ANTIBODIES, AND CONTAINER CONTAINING SUCH FORMULATIONS
JP6306588B2 (en) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Method for treating or preventing asthma by administering an IL-4R antagonist
HUE042117T2 (en) * 2012-08-21 2019-06-28 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
PL2892927T3 (en) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI755763B (en) 2013-06-04 2022-02-21 美商再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
AU2014284235C1 (en) 2013-06-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI634900B (en) 2013-07-11 2018-09-11 再生元醫藥公司 Method for treating eosinophilic esophagitis by administering an IL-4R inhibitor
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
PL3104854T3 (en) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Mast cell stabilizers for lung disease treatment
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
KR102695088B1 (en) 2014-02-28 2024-08-16 리제너론 파아마슈티컬스, 인크. Methods for treating skin infection by administering an il-4r antagonist
NO2785538T3 (en) * 2014-05-07 2018-08-04
TW201628647A (en) 2014-06-27 2016-08-16 賽諾菲公司 anti-IL4-IL13 bispecific antibody
MA40164A (en) * 2014-06-27 2017-05-03 Sanofi Sa Anti-il4-il 13 bispecific antibodies
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
HUE052606T2 (en) * 2014-12-09 2021-05-28 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 274 gene
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
CN113372446A (en) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 Antibodies for binding interleukin-4 receptor
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
ES2994774T3 (en) * 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
JP2019531308A (en) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Cromolyn composition for the treatment of pulmonary fibrosis
EP3532500A1 (en) * 2016-10-31 2019-09-04 Vectura Limited Inhalable powder composition comprising il-13 antibody
TWI857389B (en) * 2016-12-01 2024-10-01 美商再生元醫藥公司 Methods of treating inflammatory conditions
ES3052989T3 (en) * 2017-04-13 2026-01-16 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
US11970526B2 (en) * 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
KR102694419B1 (en) * 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Method for treating or preventing asthma by administering an IL-4R antagonist
WO2019097534A1 (en) * 2017-11-15 2019-05-23 Venkata Satya Suresh Attili A device and method to determine the mean/average control of asthma/copd over time and compliance to treatment
BR112020020387A2 (en) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR
CN115991781A (en) 2018-08-24 2023-04-21 江苏恒瑞医药股份有限公司 Antibodies that bind to human IL-4R, antigen-binding fragments thereof, and medical uses thereof
CN110872349A (en) * 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 Antibodies that bind human IL-4R, methods of making, and uses thereof
CN111057721B (en) 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized IL-4 and/or IL-4R alpha modified animal model
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
CN110746507B (en) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 Anti-human interleukin-4 receptor alpha monoclonal antibody and its application
CN116813770A (en) * 2018-12-27 2023-09-29 中山康方生物医药有限公司 Antibodies against human IL-4RA and uses thereof
MA55204A (en) * 2019-03-06 2022-01-12 Regeneron Pharma IL-4/IL-13 PATHWAY INHIBITORS FOR IMPROVED EFFECTIVENESS IN THE TREATMENT OF CANCER
CN113597328B (en) 2019-03-21 2025-10-31 瑞泽恩制药公司 Combination of an IL-4/IL-13 pathway inhibitor and plasma cell ablation for the treatment of allergies
SG11202111255YA (en) * 2019-05-01 2021-11-29 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
CN112010977B (en) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 Antibodies against interleukin-4 receptor (IL-4R) and uses thereof
WO2021011614A1 (en) * 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP7836754B2 (en) 2019-08-05 2026-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド A method for treating allergies and enhancing allergen-specific immunotherapy by administering IL-4R antagonists.
CN114173816A (en) 2019-08-05 2022-03-11 瑞泽恩制药公司 Method of treating atopic dermatitis by administering an IL-4R antagonist
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
KR20220110829A (en) 2019-12-09 2022-08-09 사노피 바이오테크놀로지 Methods of Treatment of Digitally Identified IL-4/IL-13 Related Disorders
CA3169959A1 (en) 2020-02-21 2021-08-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-il-4r antibody and use thereof
CN113527485B (en) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 Anti-human interleukin-4 receptor alpha antibody and preparation method and application thereof
CN114957472B (en) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 Single-domain antibody for resisting IL-4 Ralpha, application and medicine
EP4269447A4 (en) 2020-12-22 2024-07-24 Jiangsu Hengrui Pharmaceuticals Co., Ltd. COMPLEX OF ANTI-IL-4R ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
WO2023143351A1 (en) 2022-01-29 2023-08-03 上海盛迪医药有限公司 Drug conjugate of glucocorticoid
WO2025026216A1 (en) 2023-07-28 2025-02-06 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing antibody-drug conjugate of glucocorticoid
TW202535949A (en) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1356994A (en) 1963-02-08 1964-04-03 Decorative objects and process for their manufacture
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
JPH06510750A (en) 1991-05-03 1994-12-01 セラジェン　インク Molecules targeting interleukin receptors to treat inflammatory arthritis
JP3315427B2 (en) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 Dermatitis treatment
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (en) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Recombinant antibody il4 used for treatment of disorders associated with function of il4
WO2000016804A1 (en) 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002007745A1 (en) 2000-07-26 2002-01-31 Yuuzou Tsuchida Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2239203T3 (en) 2001-01-31 2005-09-16 Pfizer Products Inc. NICOTINAMIDE DERIVATIVES AND THEIR MIMETICS AS INHIBITORS OF ISOZIMAS PDE4.
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20050031609A1 (en) 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
DK1450855T3 (en) 2001-05-23 2010-01-11 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens associated with or conjugated to toxin subunits or fragments thereof
EP1461300B1 (en) 2001-11-30 2011-07-27 Biogen Idec MA Inc. Antibodies against monocyte chemotactic proteins
ES2327830T3 (en) 2002-03-29 2009-11-04 Schering Corporation ANTI-INTERLEUQUINA-5 HUMAN MONOCLONAL ANTIBODIES AND METHODS AND COMPOSITIONS CONTAINING THEM.
MXPA05005528A (en) 2002-11-26 2006-04-05 Alk Abello As Pharmaceutical allergen product.
SI2000481T1 (en) 2003-02-01 2016-08-31 Tanox, Inc. High affinity anti-human IgE antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
WO2005032399A2 (en) 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
CN1856325A (en) * 2003-09-23 2006-11-01 Pdl生物制药股份有限公司 Treatment of respiratory diseases with anti-IL-2 receptor antibodies
MXPA06004853A (en) 2003-11-07 2006-07-06 Immunex Corp Antibodies that bind interleukin-4 receptor.
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
AU2005219837A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (en) 2004-10-05 2013-07-10 源一郎 杣 Drug
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009523460A (en) 2006-01-24 2009-06-25 ドマンティス リミテッド Ligand binding to IL-4 and / or IL-13
ES2398076T3 (en) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. High affinity antibodies against the human IL-6 receptor
ES2727009T3 (en) 2006-07-21 2019-10-11 Basf Corp Pearl pigments based on synthetic mica containing ferrites
JP4221018B2 (en) 2006-08-31 2009-02-12 トヨタ自動車株式会社 Head protection airbag device
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (en) 2006-10-02 2013-03-20 瑞泽恩制药公司 High affinity human antibodies to human IL-4 receptor
US20100144646A1 (en) 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US20090062168A1 (en) 2007-08-27 2009-03-05 Joseph Timar Process for making a two-cycle gasoline engine lubricant
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
BRPI0822099A2 (en) 2007-12-21 2017-05-23 Medimmune Ltd isolated binding member, use of an isolated binding member, method for treating a disorder, isolated nucleic acid molecule, host cell, and method for producing a binding member
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110008326A1 (en) 2008-04-02 2011-01-13 Oliver Hill Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
DE202008006598U1 (en) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergy vaccine formulation for mucosal administration
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2376656A4 (en) 2008-12-01 2012-05-16 Cincinnati Children S Hospital Medical Ct METHODS FOR DETERMINING THE EFFECTIVENESS OF GLUCOCORTICOID TREATMENT OF SOSHOPHILIC OOPHAGITIS
WO2010120524A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN102596237A (en) 2009-09-07 2012-07-18 Dbv技术公司 Methods of treating eosinophilic esophagitis
CN102859288B (en) 2010-03-16 2016-09-28 阿桑尼特有限责任公司 It is applicable to reduce and is exposed to anaphylactogen and other airborne subparticle in personal breathing district and improves the temperature control type laminar airflow of sleep quality
WO2011156000A2 (en) 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
KR20130050952A (en) 2010-06-16 2013-05-16 브루스 챈들러 메이 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US20120164080A1 (en) 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
BR112013008366B1 (en) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc STABLE LIQUID PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-HUMAN INTERLEUKIN-4 ALPHA RECEPTOR ANTIBODIES, AND CONTAINER CONTAINING SUCH FORMULATIONS
UA111731C2 (en) 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. STABILIZED COMPOSITION CONTAINING ANTIBODY TO INTERLAYKIN-4 (IL-4R) RECEPTOR, OPTIONS
MX2013004212A (en) * 2010-10-15 2013-09-02 Medimmune Ltd Therapies for improving pulmonary function.
WO2012094643A2 (en) 2011-01-06 2012-07-12 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
EP2723899B1 (en) 2011-06-21 2020-11-18 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
KR20130011821A (en) 2011-07-22 2013-01-30 삼성전자주식회사 Method and apparatus for providing transaction related service
CN103974706A (en) 2011-10-06 2014-08-06 N·V·努特里奇亚 Treatment of eosinophilic esophagitis
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EP2677838B1 (en) 2012-06-18 2017-12-06 Whirlpool Corporation Microwave heating apparatus
JP6306588B2 (en) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Method for treating or preventing asthma by administering an IL-4R antagonist
PL2892927T3 (en) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN103674979B (en) 2012-09-19 2016-12-21 同方威视技术股份有限公司 A kind of luggage and articles CT safe examination system and detector assembly thereof
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
JO3532B1 (en) 2013-03-13 2020-07-05 Regeneron Pharma Anti-il-33 antibodies and uses thereof
TWI755763B (en) 2013-06-04 2022-02-21 美商再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
AU2014284235C1 (en) 2013-06-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI634900B (en) 2013-07-11 2018-09-11 再生元醫藥公司 Method for treating eosinophilic esophagitis by administering an IL-4R inhibitor
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
KR102695088B1 (en) 2014-02-28 2024-08-16 리제너론 파아마슈티컬스, 인크. Methods for treating skin infection by administering an il-4r antagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
ES2983475T3 (en) 2016-02-19 2024-10-23 Regeneron Pharma Methods for improving vaccine efficacy by administering an IL-4R antagonist
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI857389B (en) 2016-12-01 2024-10-01 美商再生元醫藥公司 Methods of treating inflammatory conditions
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
KR102694419B1 (en) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Method for treating or preventing asthma by administering an IL-4R antagonist
CN112513293A (en) 2018-05-22 2021-03-16 阿尔卡贝洛股份公司 Biomarker methods for treating atopic diseases by immunotherapy
KR102330596B1 (en) 2018-11-09 2021-11-26 아주대학교산학협력단 High Affinity Human Antibodies Against Human Interleukin-4 Receptor alpha and Uses Thereof
SG11202111255YA (en) 2019-05-01 2021-11-29 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
WO2021011614A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
KR20220110829A (en) 2019-12-09 2022-08-09 사노피 바이오테크놀로지 Methods of Treatment of Digitally Identified IL-4/IL-13 Related Disorders
US20220169739A1 (en) 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
MX2024001189A (en) 2021-07-26 2024-02-27 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist.
MX2024004762A (en) 2021-10-20 2024-05-08 Sanofi Biotechnology Methods for treating prurigo nodularis by administering an il-4r antagonist.

Also Published As

Publication number Publication date
AU2020277207A1 (en) 2020-12-24
PL4011915T3 (en) 2024-04-08
NZ744109A (en) 2023-01-27
KR20250099415A (en) 2025-07-01
IL237258B (en) 2019-12-31
SI2888281T1 (en) 2019-03-29
US9574004B2 (en) 2017-02-21
KR20150044909A (en) 2015-04-27
PL2888281T3 (en) 2019-03-29
EP4011915A1 (en) 2022-06-15
HRP20181963T1 (en) 2019-02-08
KR102386304B1 (en) 2022-04-14
KR20240101727A (en) 2024-07-02
AU2018253544B2 (en) 2020-09-17
IL312711A (en) 2024-07-01
RU2015109716A (en) 2016-10-10
ES2900342T3 (en) 2022-03-16
IL237258A0 (en) 2015-04-30
JP2023052457A (en) 2023-04-11
IN2015KN00414A (en) 2015-07-17
EP3470432B1 (en) 2021-10-06
ES2971088T3 (en) 2024-06-03
US20260055198A1 (en) 2026-02-26
JP7609901B2 (en) 2025-01-07
EP4011915B8 (en) 2023-11-15
NZ631562A (en) 2017-03-31
MX2015002292A (en) 2015-10-09
AU2020277207B2 (en) 2024-05-16
RU2018128137A (en) 2018-10-08
ES2701093T3 (en) 2019-02-20
HUE064945T2 (en) 2024-04-28
WO2014031610A1 (en) 2014-02-27
IL293398B1 (en) 2024-06-01
US20140056920A1 (en) 2014-02-27
PT3470432T (en) 2021-12-14
IL293398A (en) 2022-07-01
EP4011915B1 (en) 2023-10-11
CN110624107A (en) 2019-12-31
HK1211605A1 (en) 2016-05-27
JP2025038127A (en) 2025-03-18
NZ727717A (en) 2021-09-24
TWI656880B (en) 2019-04-21
US20180016343A1 (en) 2018-01-18
TW201420116A (en) 2014-06-01
DK2888281T3 (en) 2019-01-07
UY34984A (en) 2014-03-31
MX371344B (en) 2020-01-27
US20240199751A1 (en) 2024-06-20
US11845800B2 (en) 2023-12-19
AU2013305945A1 (en) 2015-03-12
LT2888281T (en) 2018-12-27
BR112015003590A2 (en) 2017-08-22
AR092177A1 (en) 2015-03-25
WO2014031610A8 (en) 2014-11-20
RU2018128137A3 (en) 2022-02-10
CA2882416A1 (en) 2014-02-27
EP2888281B1 (en) 2018-09-19
EP3470432A1 (en) 2019-04-17
PT4011915T (en) 2024-01-02
EP4324479A3 (en) 2024-04-24
BR112015003590A8 (en) 2017-10-31
CN104755495A (en) 2015-07-01
CA3296213A1 (en) 2026-03-02
KR20210118976A (en) 2021-10-01
JP2015527364A (en) 2015-09-17
KR20220049621A (en) 2022-04-21
EP4324479A2 (en) 2024-02-21
PL3470432T3 (en) 2022-02-07
JP2018109056A (en) 2018-07-12
JP6306588B2 (en) 2018-04-04
KR102502640B1 (en) 2023-02-23
IL293398B2 (en) 2024-10-01
RU2690675C2 (en) 2019-06-05
KR102679182B1 (en) 2024-06-28
KR20230028592A (en) 2023-02-28
PY1337526A (en) 2016-08-01
KR102307248B1 (en) 2021-10-01
NZ783258A (en) 2023-06-30
AU2024205683A1 (en) 2024-09-19
AU2013305945B2 (en) 2018-07-26
AU2018253544A1 (en) 2018-11-22
RS58091B1 (en) 2019-02-28
EP2888281A1 (en) 2015-07-01
SG11201500889TA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
IL237258A0 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
IL237328B (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
IL243246B (en) Methods for treating nasal polyposis by administering an il-4r antagonist
PT3973987T (en) Methods for treating or preventing asthma by administering an il-4r antagonist
PL2723330T3 (en) Vasoconstrictor-containing agent for combination therapy
SG10201912898XA (en) Methods for treating nasal polyposis by administering an il-4r antagonist
IL278968B (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
IL271284A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
IL247290A0 (en) Methods for treating or preventing asthma by administering an il-4r antagonist